Oncology (hepatic)
We focus on establishing an imaging biomarker for hepato-cellular carcinoma in the context of cirrhosis. The mixed modality technique of PET-MR currently holds the most promise in this regard.
Overview
Liver cirrhosis is characterized by tissue fibrosis & the conversion of normal liver architecture into structurally abnormal nodules which frequently become malignant as in the case of hepatocellular carcinoma.
Presently, CT & MR are used to detect & characterize hepatocellular carcinoma (HCC) nodules in liver cirrhosis. However, CT & MR diagnostic accuracy is limited because both detection techniques rely on nodule vascularity.
Consequently, we aim to establish an imaging biomarker which allows early & accurate detection & staging of HCC nodules before liver transplantation, as well as accurate differentiation of HCC nodules deserving treatment, from dysplastic & regenerative nodules which simply require imaging follow up.
Integrated PET & MR (PET-MR) with 11C-acetate could provide increased diagnostic accuracy in HCC nodule detection & characterization.
Research staff with an onology (hepatic) focus
Current projects
Completed projects – more info to come.
Funding organisations & groups
More info to come.